Endocrine Abstracts

Background: Liraglutide is a glucagon-like peptide analogue recently approved for use in children and young people for treating obesity. It is recommended for use within multidisciplinary weight management services, alongside dietetic and lifestyle interventions, in children over 12 years with severe obesity.Aim: To describe our experiences of using liraglutide in a tier 3 paediatric obesity service in a patient cohort who had previously failed to succes...